Theravance Biopharma
TBPH
#6963
Rank
A$0.61 B
Marketcap
Country
$12.62
Share price
0.49%
Change (1 day)
-17.07%
Change (1 year)

P/E ratio for Theravance Biopharma (TBPH)

P/E ratio as of November 2024 (TTM): 0.7368

According to Theravance Biopharma 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.736796. At the end of 2022 the company had a P/E ratio of 0.9723.

P/E ratio history for Theravance Biopharma from 2014 to 2023

PE ratio at the end of each year

Year P/E ratio Change
20220.9723-125.96%
2021-3.75-5.57%
2020-3.97-34.73%
2019-6.08-5%
2018-6.4025.01%
2017-5.12-31.78%
2016-7.50143.94%
2015-3.0853.14%
2014-2.01

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
-103-14,095.87%๐Ÿ‡บ๐Ÿ‡ธ USA
54.1 7,247.54%๐Ÿ‡บ๐Ÿ‡ธ USA
20.0 2,613.84%๐Ÿ‡บ๐Ÿ‡ธ USA
-45.5-6,281.17%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.